Piper Jaffray Begins Coverage on Aimmune Therapeutics (AIMT)

Investment analysts at Piper Jaffray assumed coverage on shares of Aimmune Therapeutics (NASDAQ:AIMT) in a research note issued to investors on Friday. The brokerage set an “overweight” rating and a $30.01 price target on the biotechnology company’s stock.

A number of other research analysts have also weighed in on the company. Zacks Investment Research lowered Aimmune Therapeutics from a “buy” rating to a “hold” rating in a research report on Friday, May 11th. Credit Suisse Group set a $47.00 price objective on Aimmune Therapeutics and gave the company a “buy” rating in a research report on Thursday, May 10th. Wedbush reaffirmed an “outperform” rating and set a $72.00 price objective on shares of Aimmune Therapeutics in a research report on Thursday, May 10th. Cantor Fitzgerald reiterated a “buy” rating and set a $64.00 target price on shares of Aimmune Therapeutics in a research note on Wednesday, May 9th. Finally, ValuEngine upgraded Aimmune Therapeutics from a “hold” rating to a “buy” rating in a research note on Monday, April 2nd. Two equities research analysts have rated the stock with a hold rating and nine have issued a buy rating to the stock. The stock has a consensus rating of “Buy” and an average price target of $53.67.

Aimmune Therapeutics opened at $30.01 on Friday, Marketbeat reports. Aimmune Therapeutics has a twelve month low of $29.62 and a twelve month high of $30.28. The company has a market cap of $1.74 billion, a P/E ratio of -11.50 and a beta of -0.36.

Aimmune Therapeutics (NASDAQ:AIMT) last posted its quarterly earnings data on Tuesday, May 8th. The biotechnology company reported ($0.92) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.71) by ($0.21). During the same quarter in the prior year, the company earned ($0.52) earnings per share. equities analysts forecast that Aimmune Therapeutics will post -2.81 earnings per share for the current year.

In other Aimmune Therapeutics news, major shareholder Bakker Juliet Tammenoms bought 9,375 shares of the business’s stock in a transaction on Thursday, February 22nd. The shares were acquired at an average cost of $32.00 per share, for a total transaction of $300,000.00. Following the purchase, the insider now owns 16,651 shares in the company, valued at approximately $532,832. The purchase was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, Director Kathryn E. Falberg bought 30,000 shares of the business’s stock in a transaction on Monday, February 26th. The shares were acquired at an average price of $32.00 per share, for a total transaction of $960,000.00. The disclosure for this purchase can be found here. Over the last quarter, insiders have acquired 58,093 shares of company stock worth $1,858,976. Company insiders own 24.56% of the company’s stock.

A number of institutional investors and hedge funds have recently modified their holdings of the business. Eventide Asset Management LLC boosted its stake in Aimmune Therapeutics by 27.6% during the 1st quarter. Eventide Asset Management LLC now owns 1,564,983 shares of the biotechnology company’s stock valued at $49,813,000 after purchasing an additional 338,983 shares during the last quarter. Legal & General Group Plc boosted its stake in shares of Aimmune Therapeutics by 55.2% in the 1st quarter. Legal & General Group Plc now owns 14,102 shares of the biotechnology company’s stock worth $449,000 after buying an additional 5,015 shares during the last quarter. Doheny Asset Management CA purchased a new position in shares of Aimmune Therapeutics in the 1st quarter worth $2,636,000. Alpine Global Management LLC purchased a new position in shares of Aimmune Therapeutics in the 1st quarter worth $1,034,000. Finally, Palo Alto Investors LP boosted its stake in shares of Aimmune Therapeutics by 18.3% in the 1st quarter. Palo Alto Investors LP now owns 1,356,514 shares of the biotechnology company’s stock worth $43,178,000 after buying an additional 210,095 shares during the last quarter. Institutional investors and hedge funds own 66.79% of the company’s stock.

Aimmune Therapeutics Company Profile

Aimmune Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes product candidates for the treatment of peanut and other food allergies. Its lead Characterized Oral Desensitization ImmunoTherapy product candidate is AR101, an investigational biologic for the treatment of patients with peanut allergy.

Analyst Recommendations for Aimmune Therapeutics (NASDAQ:AIMT)

Receive News & Ratings for Aimmune Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aimmune Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply